Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07051928 | Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP Assessment in Monocytic MDSCs.(FLIP-IMMUNO) | not yet recruiting | — | 107 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05557708 | A Safety Study of 212Pb-Pentixather Radioligand Therapy | not yet recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 |
| Jul 8, 2025 |
| clinicaltrials |
| NCT06974097 | Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy(NEO-TAN) | not yet recruiting | — | 72 | University Hospital, MontpellierOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07043907 | PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC | not yet recruiting | Phase 2 | 115 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 0 | Jul 1, 2025 | clinicaltrials |
| NCT06977828 | A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07034365 | Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung Cancer | not yet recruiting | — | 2,000 | Fudan UniversityOTHER | 0 | Jun 29, 2025 | clinicaltrials |
| NCT07042867 | Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer(LUCA-pi COHORT) | not yet recruiting | N/A | 900 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jun 29, 2025 | clinicaltrials |
| NCT06829641 | Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC | not yet recruiting | — | 200 | West China HospitalOTHER | 0 | Jun 27, 2025 | clinicaltrials |
| NCT07038460 | A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC(NEO-LISI) | not yet recruiting | Phase 2 | 134 | Wen-zhao ZHONGOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07035392 | Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 32 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT07035444 | Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer | not yet recruiting | N/A | 126 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07031154 | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07014215 | PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy | not yet recruiting | Phase 2 | 52 | Anhui Provincial Cancer HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07004712 | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer | not yet recruiting | Phase 2 | 46 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009925 | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. | not yet recruiting | Phase 2 | 38 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 8, 2025 | clinicaltrials |
| NCT07005791 | AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study | not yet recruiting | — | 142 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06998719 | Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC(ACCESS) | not yet recruiting | Phase 2 | 80 | Bi NanOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06986291 | Radiation-induced Toxicity of the Heart(CorTox) | not yet recruiting | N/A | 325 | Technische Universität DresdenOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06993896 | Physical Activity During Chemo- and/or Immunotherapy for Lung Cancer(APACHIE-01) | not yet recruiting | — | 38 | University Hospital Schleswig-HolsteinOTHER | 0 | May 29, 2025 | clinicaltrials |
| NCT06994078 | Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors | not yet recruiting | N/A | 56 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06970782 | Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure(KYLIN-3) | not yet recruiting | Phase 3 | 278 | Avistone Biotechnology Co., Ltd.INDUSTRY | 0 | May 21, 2025 | clinicaltrials |
| NCT06979661 | Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy(PORT) | not yet recruiting | Early Phase 1 | 25 | Rutgers, The State University of New JerseyOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06978153 | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 66 | Tang-Du HospitalOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT06976684 | Application of Extended Reality (XR)-Assisted CT-Guided Localization of Pulmonary Nodules in Thoracoscopic Sublobar Resection. | not yet recruiting | N/A | 20 | National Taiwan University HospitalOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06969781 | MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer | not yet recruiting | N/A | 120 | Shanghai Chest HospitalOTHER | 0 | May 14, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
| NCT06966583 | NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC(NMN) | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 12, 2025 | clinicaltrials |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 762 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT06963515 | Cutting-edge IMAGING Technologies to Improve the SAFEty and the Sustainability of LUNG Cancer Screening and the Accuracy of Non-invasive Lung Nodules Characterization | not yet recruiting | — | 250 | IRCCS San RaffaeleOTHER | 0 | May 9, 2025 | clinicaltrials |
| NCT06964503 | Impact of Psychological Stress on Treatment Response and Prognosis in Lung Cancer Patients | not yet recruiting | — | 600 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 9, 2025 | clinicaltrials |
| NCT06962189 | The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study | not yet recruiting | Phase 2 | 39 | Zhejiang UniversityOTHER | 0 | May 8, 2025 | clinicaltrials |
| NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | not yet recruiting | Phase 3 | 94 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06955325 | Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations(UPLIFT) | not yet recruiting | Phase 3 | 270 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06953765 | A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer | not yet recruiting | — | 350 | Shanghai Zhongshan HospitalOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06948539 | To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors | not yet recruiting | Phase 1 | 66 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06946836 | Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study(Neoadjuvant) | not yet recruiting | Phase 2 | 80 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06914050 | Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 25, 2025 | clinicaltrials |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06934590 | Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC | not yet recruiting | Phase 1 | 18 | GeneCraft Inc.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06929390 | Comparing BTVA and MWA in COPD With Early Lung Cancer: Efficacy and Safety | not yet recruiting | N/A | 26 | Henan Provincial People's HospitalOTHER | 0 | Apr 18, 2025 | clinicaltrials |
| NCT06925048 | SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC | not yet recruiting | Phase 2 | 86 | Chunxia SuOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06921278 | Development of the Drug and Alcohol Respiratory Health Test(DARHT) | not yet recruiting | — | 260 | King's College LondonOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06922266 | Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option(Chewbacca) | not yet recruiting | — | 20 | Ospedale San RaffaeleOTHER | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06918782 | Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma | not yet recruiting | Phase 2 | 47 | The University of Hong KongOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT01394679 | A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer | not yet recruiting | Phase 3 | 154 | Cell>Point LLCINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06908733 | Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC | not yet recruiting | Phase 2 | 30 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06909383 | Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study | not yet recruiting | Phase 2 | 41 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Apr 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2025source: clinicaltrials